Please login (Members) to view content or
(Nonmembers) this article.
0
No votes yet
Oncology Update

Oncology Update

Diane M. Otte
ONF 2012, 39(2), 221-222 DOI: 10.1188/12.ONF.221-222

Asparaginase Erwinia chrysanthemi (Erwinaze®) was approved by the U.S. Food and Drug Administration (FDA) in November 2011. The drug is indicated for patients with acute lymphoblastic leukemia (ALL) who are treated with asparaginase and who develop hypersensitivity to Escherichia coli (E. coli)-derived asparaginase. About 20% of patients with ALL develop hypersensitivity to E. coli-derived asparaginase each year. Patients can complete the full course of treatment with the use of asparaginase Erwinia chrysanthemi.

Members Only

Access to this article is restricted. Please login to view the full article.

Not a current ONS Member or journal subscriber?
Join/Renew Membership or